£37.82Tax includedLowest price in 30 days: £37.82
In stock
Orders placed before 3.30 pm are shipped on the same day
Noopept (also known as omberacetam or GVS-111) is a synthetic nootropic compound developed by the Russian pharmaceutical company JSC LEKKO Pharmaceuticals in 1996. It is classified as an ampakine, a compound that modulates AMPA and NMDA glutamate receptors, and is considered up to 1000 times more potent than Piracetam, meaning it is effective at significantly lower doses than many other nootropics.
Noopept works through multiple mechanisms, including modulating AMPA and NMDA receptors as well as acetylcholine transmission, increasing Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF) to support neuroplasticity, and enhancing Alpha and Beta brain wave activity.
Noopept, also known as omberacetam or GVS-111, is a synthetic nootropic compound developed by the Russian pharmaceutical company JSC LEKKO Pharmaceuticals in 1996. It is classified as an ampakine that modulates AMPA and NMDA glutamate receptors.
Each capsule contains 40mg of Noopept.
Noopept is considered up to 1000 times more potent than Piracetam, meaning it is effective at significantly lower doses than many other nootropics.
Noopept modulates AMPA and NMDA receptors as well as acetylcholine transmission. It also increases Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF), which support neuroplasticity.
Yes, Noopept is associated with enhanced Alpha and Beta brain wave activity.
No, Noopept lacks the structural core of true racetams, though it is often grouped alongside them due to its similar nootropic effects.
Yes, Noopept is water-soluble and crosses the blood-brain barrier readily.
Noopept was developed in 1996 by JSC LEKKO Pharmaceuticals, a Russian pharmaceutical company.
The product comes as 60 capsules per bottle, each providing 40mg of Noopept.
Take 1 capsule daily, or as directed by the manufacturer.
No product reviews yet — add the first one!